Insulin resistance is highly prevalent among patients with atherosclerosis and is associated with an increased risk for myocardial infarction (MI) and stroke. The IRIS trial (Insulin Resistance Intervention after Stroke) demonstrated that pioglitazone decreased the composite risk for fatal or nonfatal stroke and MI in patients with insulin resistance without diabetes mellitus, after a recent ischemic stroke or transient ischemic attack. The type and severity of cardiac events in this population and the impact of pioglitazone on these events have not been described.
I
nsulin resistance is a common condition in which intracellular insulin signaling is impaired, resulting in compensatory hyperinsulinemia and, eventually, hyperglycemia and type 2 diabetes mellitus in those who also develop relative insulin secretory impairment. Risk factors include family history, older age, central obesity, and greater weight. In epidemiological research, insulin resistance is associated with an increased risk for both myocardial infarction (MI) and stroke. This condition is highly prevalent in patients with established cardiovascular disease. [1] [2] [3] We recently reported that insulin resistance was present in 63% of patients without diabetes mellitus after a recent ischemic stroke or transient ischemic attack (TIA). 4 Because of the strong association of insulin resistance with vascular disease, there is emerging interest in whether interventions that ameliorate insulin resistance reduce cardiovascular risk in patients without diabetes mellitus.
The most effective drugs for reducing insulin resistance are the thiazolidinedione class of peroxisome proliferator-activated receptor γ agonists, which include pioglitazone and rosiglitazone. 5 Both drugs improve insulin sensitivity, prevent (or delay) diabetes mellitus in patients at risk, and improve glycemic control in patients with established type 2 diabetes mellitus. One of them, pioglitazone, has been shown to prevent clinical macrovascular events in patients with cerebrovascular disease. In 2005, the PROactive trial (Prospective Pioglitazone Clinical Trial in Macrovascular Events) of patients with diabetes mellitus, found that pioglitazone reduced risk for a secondary outcome of cardiovascular mortality and nonfatal stroke or MI by 28% (P=0.047) in the subgroup who entered with a history of stroke. 6 The IRIS trial (Insulin Resistance Intervention after Stroke) extended the evidence for the effectiveness of pioglitazone to patients with insulin resistance without diabetes mellitus and a recent stroke or TIA. In comparison with placebo, pioglitazone reduced insulin resistance, prevented onset of diabetes mellitus, improved high-sensitivity C-reactive protein, and reduced the risk for the primary outcome of fatal or nonfatal stroke or MI by 24% (P=0.007). 4 Pioglitazone, in comparison with glimepiride, reduces the progression of coronary atherosclerosis in patients with type 2 diabetes mellitus. 7 Pioglitazone also reduces coronary inflammation, 8 alters coronary plaque composition by reducing necrotic core, 9, 10 and prevents intimal hyperplasia after coronary stenting, 11, 12 in patients with and without diabetes mellitus. Thus, in this analysis of the IRIS study, we tested the hypothesis that pioglitazone's coronary artery antiatherosclerotic and potential vascular stabilizing effects might result in the reduction of acute coronary syndromes in insulin-resistant patients. We analyzed the effects of pioglitazone treatment on the incidence and timing of cardiac ischemic events, including spontaneous type 1 MI, using the 2012 Third Universal definition of MI. 13 
METHODS

Study Participants
The design and primary results of IRIS have been published. 4, 14 The study was approved by the Yale Human Investigation Committee, and institutional review boards at each of the participating sites, and the participants gave written informed consent. In this multinational, double-blind, placebo-controlled trial, patients were required to have had a qualifying ischemic stroke or TIA within 6 months of randomization and insulin resistance as defined by a value >3.0 on the Homeostasis Model Assessment-Insulin Resistance ([fasting insulin, μU/mL × fasting glucose, mmol/L] /22.5). This threshold was chosen because it identifies the highest quartile among populations without diabetes mellitus. 15, 16 Because insulin sensitivity is impaired after a week of bedrest 17 and may be impaired for 2 weeks following a stroke, 18 the screening blood test was conducted at least 14 days after the index event. Patients with diabetes mellitus were excluded. Diabetes mellitus was defined if a patient was taking medication for diabetes mellitus within 90 days of screening, met (2005) American Diabetes Association criteria 19 for
Clinical Perspective
What Is New?
• The IRIS trial (Insulin Resistance Intervention after Stroke) compared the effects of pioglitazone with placebo on major cardiovascular events after stroke or transient ischemic attack in patients without diabetes mellitus who had evidence of insulin resistance.
• IRIS showed that pioglitazone improved insulin resistance, prevented diabetes mellitus, improved C-reactive protein, and reduced fatal or nonfatal stroke or myocardial infarction.
• This secondary analysis of IRIS examined the effect of pioglitazone on acute coronary syndromes (myocardial infarction or unstable angina).
• Pioglitazone reduced the risk of these events by 29%, with benefit emerging after 2 years of treatment.
• Pioglitazone reduced the incidence of type 1 (spontaneous) myocardial infarction, with a neutral effect on type 2 (demand-related) myocardial infarction.
What Are the Clinical Implications?
• Insulin resistance is highly prevalent among patients with stroke who do not have diabetes mellitus and is a marker of subsequent cardiovascular risk.
• The present analysis suggests that pioglitazone may stabilize coronary atheroma in such patients and may serve as a useful secondary prevention therapy in addition to statins, aspirin, and other established treatments.
diabetes mellitus (fasting plasma glucose ≥7 mmol/L [126 mg/dL], confirmed by repeat test), or had a hemoglobin A1c ≥53 mmol/mol (7.0%) at screening. Patients with heart failure were excluded because of the potential for fluid retention related to pioglitazone therapy. 14 In the initial protocol, patients with New York Heart Association class III or IV heart failure or class II heart failure with reduced ejection fraction were excluded in accordance with a 2003 consensus statement from the American Heart Association and American Diabetes Association. 20 In 2008, the exclusion was again expanded to patients with any history of heart failure, and previously randomly assigned participants with a history of heart failure were permanently removed from the study drug. The trial was monitored by an independent data and safety-monitoring board appointed by the funding agency, the National Institute of Neurological Disorders and Stroke.
Study Procedures
Eligible participants were randomly assigned in a 1:1 ratio to pioglitazone or matching placebo. Contingent on the absence of signs and symptoms of heart failure or fluid retention, study medication was titrated over 8 weeks from 15 mg daily to a target dose of pioglitazone 45 mg daily or matching placebo. If participants subsequently reported shortness of breath, excessive weight gain, or edema, study drug was reduced or discontinued according to prespecified algorithms. Any patient who developed heart failure was removed from the study drug even if their symptoms had improved with dose reduction or diuretic therapy.
Cardiac Outcomes
The primary outcome in IRIS was time to first fatal or nonfatal stroke or MI. Time to first episode of acute coronary syndrome (ACS), defined as acute MI or unstable angina, was a prespecified secondary outcome for IRIS.
When IRIS was initiated in 2005, the original protocol used criteria for cardiac outcomes that were based on the 2000 Consensus Conference of the European and American Colleges of Cardiology for MI 21 and definitions used in the AFCAPS/ TexCAPS study (Air Force/Texas Coronary Atherosclerosis Prevention Study) for unstable angina. 22 In 2012, the Third Universal Definition of Myocardial Infarction 13 was published. It is considered the current standard for diagnosis of MI and provides criteria for 5 subcategories of MI based on presumptive pathophysiologic mechanisms. Following its publication, the IRIS Operations and Steering Committees agreed to prespecify an additional secondary analysis evaluating the effect of pioglitazone on acute MI according to the revised definition. The data and safety-monitoring board appointed by the National Institute of Neurological Disorders and Stroke was aware of this decision. The online supplement provides detailed criteria for cardiac outcomes (online-only Data Supplement Table I ). Each suspected cardiac event (unstable angina or myocardial infarction) was adjudicated by an independent external committee that was blinded to treatment assignment. Events were adjudicated using both the 2000 and 2012 criteria for MI. Two blinded investigators (L.H.Y., J.C.) independently extracted information on the type, setting, and maximal level of troponin elevation for events meeting the updated 2012 criteria for MI. Any differences were reconciled by consensus.
Statistical Analysis
The time to the first episode of adjudicated ACS (MI or unstable angina), MI alone, and unstable angina alone, were analyzed by intention to treat. In time-to-event analyses, patients without outcome events were censored at the date of the last completed follow-up contact. Cumulative event-free rates were calculated by the method of Kaplan-Meier, 23 and treatment group differences were tested by the log-rank statistic using a type I error of 0.05 (2-sided). The effect of pioglitazone relative to placebo was estimated as a hazard ratio (HR) from a Cox model 24 with 95% confidence intervals (CIs). We examined the effect of pioglitazone on the risk of MI overall, and according to the presence or absence of ST-segment elevation, the setting (MI type), and the level of troponin elevation. In exploratory analysis, we also examined the risk of a clinically important MI, defined as an event associated with ST-segment elevation, troponin increase >100× upper limit of normal (ULN) or death, by treatment group. The decision to perform these analyses was made in all cases before evaluating the effect of study drug on outcome. In the primary report of IRIS, the outcome of ACS was 1 of 5 time-to-event secondary outcomes, and was accordingly adjusted for multiple testing. 4 In this report, the analyses of ACS outcomes using the 2012 MI criteria were not adjusted for multiplicity. SAS version 9.3 was used for all analyses (SAS Institute Inc.).
RESULTS
Baseline Characteristics
The IRIS cohort included 3876 participants with either ischemic stroke (3375, 87.1%) or TIA (483, 12.5%) who were randomly assigned at 179 sites in 7 countries between February 2005 and January 2013. 4 Randomization yielded treatment groups with similar features at baseline (Table 1) . Mean age was 63.5 years, 65.5% were men, 11.6% were black, and 3.8% were Hispanic. Mean fasting glucose concentration was 5.5±0.6 mmol/L and hemoglobin A1C was 5.8±0.4%. Median values for insulin and Homeostasis Model Assessment were 19 μU/ mL (interquartile range=16-25) and 4.6 (interquartile range=3.7-6.2), respectively. Prediabetes defined by fasting glucose ≥5.5 mmol/L, but <7.0 mmol/L, was present in 41.6% of subjects. No participants were taking antihyperglycemic agents at baseline.
Cardiac risk factors were common but were generally well controlled with medications (Table 1) . A history of hypertension was present in 71.5% of participants, and 41.9% were taking an angiotensin-converting enzyme inhibitor, 14.1% an angiotensin receptor blocker, 31.8% a β-blocker, 26.4% a thiazide diuretic, and 26.9% other antihypertensive therapy. At baseline, 82.5% of participants were using statins, 2.9% fibrates, and 6.4% other lipid-lowering therapies. Mean values for low-density lipoprotein (LDL) cholesterol, high-density lipoprotein cholesterol, and triglycerides were 2.3±0.8 mmol/L, 1.2±0.3 mmol/L, and 1.6±0.8 mmol/L, respectively. Median Creactive protein was 2.2 (interquartile range=1.0-4.9).
Current cigarette use at baseline was reported by 16.1% of participants.
Although all participants qualified for the trial with an ischemic stroke or TIA, only 462 (11.9%) participants had a prior history of coronary artery disease based on hospitalization for MI, coronary angioplasty or stenting, or coronary artery bypass grafting. In addition, 287 (7.4%) participants had a history of carotid artery intervention.
Antiplatelet agents were used by 3558 (92%) participants, including 1901 on aspirin alone, 929 on aspirin Data are presented as mean±SD if normally distributed, otherwise median (25th percentile, 75th percentile) are reported. Number of participants with missing data (pioglitazone, placebo): Black race (33, 33) ; Hispanic (12, 8) ; prior stroke (1,2); hypertension history (1,1); myocardial infarction history (3,3); coronary intervention (1,1); carotid intervention (1,1); body mass index (6,6); atrial fibrillation (2,0); blood pressure (6,6); LDL (21, 17) ; HDL (5,3); triglycerides (4,3); C-reactive protein (17, 12) ; and prescription medications (7, 5) . ACE indicates angiotensin-converting enzyme; HbAlc, hemoglobin A1c; HDL, high-density lipoprotein; HOMA-IR, Homeostasis Model Assessment-Insulin Resistance; and LDL, low-density lipoprotein.
*Carotid endarterectomy, angioplasty, or stenting before or after index event.
(Continued ) and another antiplatelet agent, and 728 on a nonaspirin antiplatelet agent alone. Oral anticoagulation therapy was used in 441 (11.4%) participants. Atrial fibrillation was not an exclusion for randomization because of the residual risk for recurrent stroke in these patients despite anticoagulation therapy. 25 There was a history of atrial fibrillation in 264 (6.8%) participants, of whom 227 were on anticoagulant therapy and 36 were on antiplatelet drugs.
During the initial recruitment phase, 19 participants with New York Heart Association class I to II heart failure symptoms without a reduced left ventricular ejection fraction (<40%) were randomly assigned; all were subsequently withdrawn from study drug in 2008 according to protocol but were retained in follow-up and are included in the analysis. Follow-up completed was similar in the pioglitazone and placebo groups: 7951 and 7952 person-years, respectively. A total of 301 patients became lost to follow-up (ie, missed >12 months of follow-up) because of withdrawal of consent or becoming unable to be located (165 patients in the pioglitazone group missed 501 person-years and 136 patients in the placebo group missed 435 patient-years) (online-only Data Supplement Figure I ).
Cardiac Outcomes
Patients were randomly assigned a median of 80 days after the index event and followed for a median of 4.8 years. The incidence of ACS using the 2012 MI criteria was 5.1%, including 0.1% with fatal MI, 3.1% with nonfatal MI, and 1.9% with unstable angina (Table 2) . Of the 141 MIs, 28 were ST-segment-elevation MIs, 98 were non-ST-segment-elevation MIs, and 15 events could not be classified because of inadequate information (Table 3 ). The setting of the MI was spontaneous (type 1) for 94 events, myocardial oxygen supply/demand imbalance (type 2) for 43, sudden death without biomarker ascertainment (type 3) in one, and after percutaneous coronary intervention (type 4a) in one other (Table 3) . Serum troponin elevation was minimal (<3× ULN) in 20, mild (3-10× ULN) in 32, moderate (10-100× ULN) in 49, and severe (>100× ULN) in 39 MI events (Table 3) . Severe troponin elevation was more common with type 1 MI (34 of 94) in comparison with type 2 MI (5 of 45) (χ 2 P =0.002) (online-only Data Supplement Table I ). Of the 128 participants with MI after randomization, 25% had reported a history of coronary artery disease at randomization; for the remaining 75%, the MI event was the first manifestation of coronary artery disease.
Effect of Pioglitazone on Cardiac Outcomes
Using 2012 criteria for MI, there were a total of 99 ACS events (61 MIs and 38 episodes of unstable angina) in 83 participants in the pioglitazone group in comparison with 126 events (80 MIs and 46 episodes of unstable angina) in 116 participants in the placebo group (HR, 0.71; 95% CI, 0.54-0.94; P=0.02) ( Table 2 ). Pioglitazone was associated with a similar directional change in each component of ACS, with a reduction in fatal MI, nonfatal MI, and unstable angina events (Table 2) . ACSfree survival curves showed separation after 2 years (P=0.02) ( Figure 1A ). The effect of pioglitazone on ACS risk was uniform across most subgroups examined, including patients with and without impaired fasting glucose and Homeostasis Model Assessment values above and below the median, and by use of cardiovascular therapies, including statins, renin-angiotensin-aldosterone system inhibitors, and aspirin ( Figure 2) . Pioglitazone was associated with a reduction in ACS events in patients without a history of coronary artery disease at baseline (HR, 0.66; 95% CI, 0.47-0.93), with a similar trend in the smaller subgroup with a history (HR, 0.80; 95% CI, 0.48-1.33). In patients with no history of hypertension at baseline, the hazard ratio was significantly lower (HR, 0.36; 95% CI, 0.18-0.72) than the hazard ratio observed in patients with a history of hypertension (HR, 0.84; 95% CI, 0.62-1.15) (P value for interaction=0.03). Because P values were not adjusted for multiple testing, this finding may be attributable to chance.
The risk for MI was lower in the pioglitazone group than in the placebo group, but did not reach statistical significance (HR, 0.73; 95% CI, 0.51-1.03; P=0.08) ( Table 2 ). However, pioglitazone significantly reduced the risk of spontaneous type 1 MI (HR, 0.62; 95% CI, 0.40-0.96; P=0.03). In contrast, there was no effect of pioglitazone on type 2 MI (HR, 1.05; 95% CI, 0.58-1.91; P=0.87) (Table 3, Figure 1B and 1C) . In a prespecified exploratory analysis, pioglitazone had a greater effect in reducing risk for MI events associated with ST-segment elevation, troponin increase >100× ULN, or death (18 versus *P value is from test for interaction between treatment and each subgroup unadjusted for multiplicity. †Participants with HbA1c <7.0%, the usual target for treatment, were permitted to enroll. ACE indicates angiotensin-converting enzyme; ADA, American Diabetes Association; ARB, angiotensin receptor blocker; CI, confidence interval; Hb, hemoglobin; HOMA, Homeostasis Model Assessment; HR, hazard ratio; and Pts., patients.
( Table 3 and online-only Data Supplement Table II) . Among patients with MI in the placebo group, median peak troponin was 37× ULN; among patients with MI in the pioglitazone group it was 15× ULN (Wilcoxon ranksum P=0.18).
Effect of Pioglitazone on Cardiac Outcomes Using the Original IRIS Criteria
The IRIS trial was initiated before the 2012 Third Universal Definition of MI. The original IRIS MI criteria had a higher troponin threshold (>2× for spontaneous MI) and included patients with presumed sudden cardiac death. Adjudications based on the original IRIS criteria resulted in the reclassification of 47 events: 12 nonfatal MIs changed to episodes of unstable angina, 3 nonfatal MIs changed to no event, 8 ruled-out events changed to nonfatal MI, and 24 ruled-out events changed to presumed sudden cardiac death (ie, fatal MI). Despite these differences in the adjudication criteria, the beneficial effect of pioglitazone on ACS outcomes was very similar to that using the 2012 Third Universal Definition of MI (unadjusted HR, 0.75; 95% CI, 0.57-0.97; P=0.03) ( Table 4 , online-only Data Supplement Figure II) .
DISCUSSION
This analysis of the results of the IRIS trial provides insight into the characteristics of ACS that occur after ischemic stroke or TIA. Importantly, it also demonstrates that pioglitazone, a thiazolidinedione class peroxisome proliferator-activated receptor γ agonist with potent insulin-sensitizing effects, reduced the risk of ACS, particularly the most serious events in insulin-resistant patients without diabetes mellitus. These findings were evident for both ACS components (ie, unstable angina and MI). The beneficial effect of pioglitazone was most prominent in spontaneous type 1 MI, with no effect observed on type 2 MI. When we dichotomized MI according to severity, pioglitazone was more effective in preventing more clinically significant MIs characterized by ST-segment elevation, troponin > 100× ULN, or death. Coronary artery disease is relatively common in patients with ischemic stroke, and these individuals are known to be at risk for subsequent cardiac events. 28, 29 Only 12% of IRIS participants had a prior history of coronary artery disease (defined as MI, percutaneous coronary artery intervention, or coronary artery bypass grafting). As expected, these subjects were at greater risk for ACS events than patients without such a history (14.5% versus 4.9% in placebo group). Nonetheless, pioglitazone was associated with a significant reduction in ACS events in the larger subgroup of patients without preexisting coronary artery disease.
The risk reduction for ACS in IRIS occurred despite broad use of background evidence-based cardiovascular preventive therapies, including statins, antiplatelet agents, and antihypertensive drugs. These results indicate that a substantial portion of residual coronary risk in patients with insulin resistance without diabetes mellitus is modifiable by additional treatment with pioglitazone. The reduction in ACS risk in IRIS was independent of effects on LDL cholesterol; in fact, pioglitazone slightly increased LDL cholesterol. 4 Although thiazolidinediones increase LDL cholesterol, they have little effect on particle number, but rather increase LDL particle size, which may render LDL less atherogenic. 30 It is important to note that 82% of our patients were on statins, a therapy shown in the SPARCL trial (Stroke Prevention by Aggressive Reduction in Cholesterol Levels) of high-dose atorvastatin to be effective after stroke for reducing risk of both recurrent stroke and ACS. 29 Furthermore, because of the widespread use of statins in IRIS, LDL concentrations remained in a desirable range in both treatment groups during follow-up (overall mean±standard error, 2.32±0.02 mmol/L in the pioglitazone group and 2.28±0.02 mmol/L in the placebo group).
Pioglitazone appeared to be particularly effective in reducing the more clinically important ACS outcomes, defined as MIs associated with ST elevation, large troponin increase (>100× ULN) or death. Moreover, pioglitazone reduced the incidence of spontaneous (type 1) MI events, but not those induced by supply/demand imbalance (type 2). The former finding suggests a benefit of pioglitazone to stabilize coronary atheroma, possibly through anti-inflammatory effects. Pioglitazone is known to reduce coronary arterial inflammation, 8 and, in the IRIS trial, pioglitazone reduced C-reactive protein by 25% at 1 year after randomization. 4 The latter finding is notable because the vast majority (82%) of patients were already treated with statins. Pioglitazone may also have acted to reduce type 1 MI by retarding the progression of atherosclerosis, 7 reducing the necrotic core of plaques, 9, 10 or exerting antithrombotic effects. 31 In contrast, pioglitazone did not appear to prevent type 2 MIs, which were characterized by lower levels of troponin elevation. This category of MI is usually attributed to hemodynamic or metabolic stress (eg, sepsis, trauma, gastrointestinal bleeding, rapid atrial fibrillation, and hypoxemia), which may not have been affected by pioglitazone treatment. Alternatively, pioglitazone might have had coronary atheroprotective and anti-inflammatory actions that were counterbalanced by volume expansion, anemia, or minor reductions in blood pressure, 4 resulting in a neutral overall effect on the incidence of type 2 MI.
Our primary analysis of ACS events used the Third Universal Definition of MI criteria, which were published in 2012 13 during the course of the trial. This was a prespecified analysis, but we also evaluated the results using the originally designated IRIS study criteria 14 that were based on the 2000 Consensus Conference criteria. 21 Overall, these analyses yielded very similar point estimates for the benefit of pioglitazone on both ACS and MI events. Although the 2012 criteria are now considered the standard for clinical trials, the convergence of results using the original IRIS criteria provide additional support for a therapeutic benefit of pioglitazone. The 2012 criteria are more conservative in excluding patients with presumed sudden cardiac death, but are arguably less stringent in including events with troponin elevations in the 1 to 2× ULN range, these being categorized as unstable angina with the 2000 criteria.
Although IRIS is the first study to demonstrate the efficacy of pioglitazone for reducing risk of ACS in patients with insulin resistance without diabetes mellitus after stroke or TIA, pioglitazone had been shown previously to have benefit in preventing cardiovascular complications in patients with macrovascular disease and type 2 diabetes mellitus. 32 In a post hoc analysis of the PROactive study, among the entire cohort, pioglitazone reduced the risk of the composite outcome of cardiac death, nonfatal MI, and ACS. 33 Taken together with the current analysis, these data support the efficacy of pioglitazone for prevention of cardiovascular events in patients with vascular disease and a metabolic disorder as manifested by either diabetes mellitus or insulin resistance.
Limitations of the current analysis warrant consideration. First, IRIS was designed to test the effects of pioglitazone on the composite outcome of stroke and MI and was not powered adequately to show an effect on MI alone. Although ACS (including both MI and unstable angina) was a prespecified secondary end point, the statistically significant benefit of pioglitazone on ACS was demonstrated without adjustment for multiple secondary outcomes. Second, similar to prior stroke trials, 29, 34, 35 there was loss to follow-up in IRIS patients; although the missingness of follow-up was similar, we cannot exclude the possibility that outcome events were differentially missed in the 2 treatment groups. Third, it remains uncertain whether the benefits of pioglitazone were related to insulin sensitization, additional effects of peroxisome proliferator-activated receptor γ activation, or other pharmacological effects of pioglitazone. Fourth, it is uncertain whether pioglitazone would be effective as secondary prevention therapy after MI or ACS, as opposed to stroke or TIA. Last, the overall benefit of pioglitazone on cardiovascular outcomes needs to be considered in the context of the side effects of weight gain, edema and bone fracture. 4 Heart failure is also a known risk associated with pioglitazone therapy. 32 Although the incidence of serious heart failure was not increased in IRIS, 4 this may reflect the exclusion of patients with preexisting heart failure, as well as postrandomization procedures to reduce dose or discontinue treatment for excessive weight gain or edema, and to discontinue study drug for heart failure.
In conclusion, this analysis of the IRIS trial demonstrates that pioglitazone reduced the risk of ACS in patients with insulin resistance without diabetes mellitus after ischemic stroke or TIA. This benefit was derived from a reduction in the incidence of spontaneous type 1 MI, suggesting coronary artery plaque stabilization. The results warrant consideration as clinicians weigh the potential benefits and risks of pioglitazone as a secondary prevention therapy in patients with insulin resistance and cardiovascular disease.
